SCHEDULE: Sio Capital Amends PMV Pharma Stake to 4.98%

Sio Capital Management, LLC has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.98% in PMV Pharmaceuticals, Inc. as of September 30, 2025.

Summary

• Sio Capital Management, LLC reported beneficial ownership of 2,636,548 shares of PMV Pharmaceuticals, Inc. common stock.
• This represents 4.98% of the outstanding common stock.
• The calculation is based on 52,990,864 shares outstanding as of August 6, 2025, as reported in PMV Pharmaceuticals' Form 10-Q.
• Sio Capital Management, LLC holds shared voting power and shared dispositive power over all reported shares.
• Sio Capital Management, LLC is a registered investment adviser.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a routine disclosure of beneficial ownership, indicating a passive investment. It does not inherently convey positive or negative sentiment about the issuer's performance or prospects.

Industry Context

Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock, indicating a passive investment intent. This filing updates Sio Capital Management's stake in PMV Pharmaceuticals, a common practice for investment advisers managing client portfolios.

Stakeholder Impact

• Shareholders of PMV Pharmaceuticals, Inc. are informed of a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

PMV Pharmaceuticals, Sio Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Equity Stake, SEC Filing